Insurer Cannot Deny Claims Based on Unrelated Pre-existing Ailments: Delhi Consumer Commission Rules

In a significant ruling aimed at curbing questionable insurance claim denials, the District Consumer Disputes Redressal Commission, South-II, Delhi , has directed Tata AIG Insurance Company Ltd. to honor a life-altering medical claim. The Commission, led by President Monika Aggarwal Srivastava along with members Dr. Rajender Dhar and Ritu Garodia, condemned the insurer for failing to demonstrate a medical nexus between a policyholder's past health history and his subsequent cancer diagnosis.

The Background: A Home Loan and a Health Crisis In early 2023 , Moidadin obtained a home loan of Rs 23,50,000 from AU Small Finance Bank . To secure this financial liability, he opted for a "Group Credit Secure Plus Medical Insurance Policy" through Tata AIG, covering critical illness, accidental death, and disability. However, within months of the policy inception, life took a tragic turn. On August 24, 2023 , the policyholder was admitted to a hospital and diagnosed with lung cancer, a condition so severe it required the surgical removal of an entire lung.

When he sought the contractually promised relief to settle his outstanding loan, the insurer hit back with a denial. Citing " non-disclosure of facts " about a 2020 heart ailment—specifically coronary artery disease—the insurance giant repudiated the claim and canceled the policy ab initio , effectively claiming that the policyholder had misrepresented his health status at the time of purchase.

Arguments from Across the Aisle The insurance company maintained that its decision was based on strict adherence to the contract, arguing that the failure to disclose the 2020 heart surgery constituted a suppression of material facts , which justified the cancellation of the policy. The insurer further attempted to dismiss the case by pointing to a lack of necessary parties, notably the omission of the bank that facilitated the policy.

Conversely, the complainant argued that his heart condition from three years prior had absolutely no medical connection to the lung cancer that emerged in 2023 . He contended that the insurer was leveraging a technical loophole to avoid its core obligation of providing financial security, an act he categorized as a clear service deficiency .

The Commission’s Legal Analysis The Commission’s analysis turned on the medical evidence presented. After reviewing the case, the bench reached a definitive conclusion: the two ailments were clinically distinct.

Addressing the insurer's aggressive stance, the Commission observed that there was no valid reason to link a cardiac issue from 2020 to lung cancer in 2023 . The panel highlighted that the insurer failed to provide any expert medical evidence to establish that the previous heart condition contributed to or led to the subsequent cancer. By attempting to draw a "remote and speculative connection," Tata AIG fundamentally failed its duty to provide transparent and fair service.

Key Observations The Commission pulled no punches in its assessment of the insurer’s conduct:

"The heart disease was diagnosed in 2020 and the lung cancer was diagnosed after a gap of nearly three years... [these] cannot be medically correlated with each other."

"OP has attempted to draw a remote and speculative connection between the two ailments, which otherwise have no medical correlation."

"This Commission is of the considered opinion that the OP not adopted fair, transparent, and consumer-friendly approach towards the complainant and thus has adopted unfair trade practice ."

The Verdict and Its Impact The Commission ruled in favor of the policyholder, ordering Tata AIG to pay the full sum insured of Rs 23,50,000 within two months. Furthermore, the insurer was ordered to pay Rs 25,000 as compensation for the mental agony caused by their " unfair trade practice " and an additional Rs 5,000 toward litigation costs .

This ruling serves as a vital precedent, reminding insurers that they cannot use vague arguments of "non-disclosure" to avoid liabilities when the alleged suppression has no actual clinical nexus with the claim at hand. For consumers, the decision bolsters the protection against arbitrary claims processing and reinforces the principle that insurance contracts must be interpreted and enforced with fairness rather than predatory obstructionism.